Actively Recruiting
A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region
Led by Bristol-Myers Squibb · Updated on 2024-07-23
1500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the comparative effectiveness of two drugs, deucravacitinib and apremilast, in adults with plaque psoriasis. This observational study aims to understand how these treatments perform in real-world settings to help improve management of plaque psoriasis. The study is sponsored by Bristol-Myers Squibb and focuses on adults who have recently started treatment with either drug. Participants are grouped based on the treatment they have initiated: one group taking deucravacitinib and another taking apremilast. Each medication is prescribed by the participant's clinician as part of their regular care. The study observes participants for up to 60 months, tracking changes over time while participants remain on their prescribed treatment or until they discontinue. During the study, participants will have assessments at baseline and every six months, including measurements of body surface area affected by psoriasis, investigator global assessment, and quality of life using the Dermatology Life Quality Index. Researchers will also monitor treatment continuation time and various psoriasis severity scores. This long-term follow-up aims to capture comprehensive data on treatment effects and participant well-being throughout the study period.
CONDITIONS
Brief Title
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have been diagnosed with plaque psoriasis by a dermatologist
- Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
- Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes
You will not qualify if you...
- Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
- Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 60 months or until treatment discontinuation
Participants who have initiated deucravacitinib or apremilast are observed to assess treatment effectiveness and safety over time.
Visits every 6 months
Trial Site Locations
Total: 1 location
1
Local Institution
Waltham, Massachusetts, United States, 02451
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
F
First line of the email MUST contain the NCT# and Site #.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here